...
首页> 外文期刊>Medicine. >The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer
【24h】

The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer

机译:外显子19缺失患者临床特征与NONSMALL细胞肺癌L858R突变之间的临床特征差异

获取原文
获取原文并翻译 | 示例

摘要

Recent studies have demonstrated that exon 19 deletion (19 Del) and exon 21 L858R mutation (L858R) are 2 different types of sensitive epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung cancer (NSCLC). However, whether there are some differences between those 2 groups in baseline clinical characteristics is still unclear.We enrolled consecutive 1271 NSCLC patients detected with either 19 Del or L858R and collected their baseline clinical characteristics including age, sex, comorbidity, smoking and drinking status, body mass index (BMI), TNM stage, histologic type, differentiation, tumor maximum diameter (TMD), and CEA level. (2) test and multivariate logistic regression analysis were used to compare the difference.We found a higher percentage of 19 Del in younger patients group (<=50 yr) than L858R (P<0.001) through (2) test. Besides, patients with 19 Del have higher risk of lymph node metastasis (P<0.001). However, there were no significant differences in other items of clinical characteristics between 19 Del and L858R. Multivariate analysis showed similar significant results. Subgroup analysis in different age groups (10 yr as an interval) and N stages (stratified by N0, N1, N2, and N3) also indicated above-mentioned trends.NSCLC patients with 19 Del are more likely to be young and have lymphatic metastasis than those with L858R. Age and N stage might be considered in predicting EGFR mutation type in NSCLC.
机译:最近的研究表明,外显子19缺失(19Del)和外显子2118R8R突变(L858R)是非物质细胞肺癌(NSCLC)中的2种不同类型的敏感表皮生长因子受体(EGFR)突变。然而,基线临床特征中的那些2组之间是否存在一些差异仍然不清楚。我们纳入连续1271名NSCLC患者,用19 del或L858R检测到,并收集其基线临床特征,包括年龄,性别,合并症,吸烟和饮酒和饮酒等,体重指数(BMI),TNM阶段,组织学型,分化,肿瘤最大直径(TMD)和CEA水平。 (2)试验和多变量逻辑回归分析用于比较差异。我们发现比L858R(P <0.001)通过(2)试验更高的患者组(<= 50yr)百分比的19 del百分比。此外,患者患有19 del的患者具有更高的淋巴结转移风险(P <0.001)。然而,19 del和l858r之间的其他临床特征的其他项目没有显着差异。多变量分析显示出类似的显着结果。不同年龄组的亚组分析(10 YR作为间隔)和n阶段(由N0,N1,N2和N3分层)也表明了上述趋势。患有19 Del的患者更有可能年轻并且具有淋巴转离症比L858R的那些。在NSCLC中预测EGFR突变类型,可能考虑年龄和n阶段。

著录项

  • 来源
    《Medicine. 》 |2015年第44期| 共8页
  • 作者单位

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

    Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医药、卫生 ;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号